-
June 19, 2013
Novo Nordisk announced that the US Court of Appeals for the Federal Circuit has found the patent on its diabetes ...
-
June 18, 2013
Novartis recently presented positive results on oncology drug Jakavi from a three-year follow up analysis of a phase ...
-
June 18, 2013
Incyte announced positive long-term data from two ongoing studies on Jakafi.
-
June 18, 2013
The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase ...
-
June 17, 2013
The pricing and reimbursement conditions for InterMune's Esbriet was approved in Italy.
-
June 14, 2013
Novartis recently presented new data on Gilenya from a phase III study, TRANSFORMS.
-
June 13, 2013
PDL BioPharma announced that it expects to receive second quarter 2013 royalty revenues of around $143 million.
-
June 12, 2013
Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
-
June 12, 2013
Shares of Questcor received a major boost when the company announced the acquisition of development and ...
-
June 10, 2013
Novartis (NVS) recently released encouraging data on its pipeline candidate, LDK378, from a phase I study.
-
June 10, 2013
In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
-
June 10, 2013
Actavis is looking to launch its generic versions of Diprivan and Safyral.
-
June 08, 2013
It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on ...
-
June 07, 2013
Novartis recently announced positive results on Afinitor, from a phase III trial, BOLERO-3 (Breast cancer trials of ...
-
May 03, 2013
Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
-
February 15, 2013
Incyte Corporation's (INCY) second-quarter 2012 earnings of 3 cents per share compared favorably with the year-ago ...
-
February 13, 2013
Saudi Aramco Lubricating Oil Refining Co. (Luberef), recently awarded Jacobs Engineering Group Inc. (JEC), a ...
-
February 08, 2013
Hologic (HOLX) reported net income of $3.1 million or a penny per share in the first quarter of fiscal 2013 compared ...
-
February 04, 2013
Recently, GlaxoSmithKline (GSK) announced the initiation of a phase III study (COMBI-AD) to evaluate its oncology ...
-
February 04, 2013
Valeant Pharmaceuticals International, Inc. (VRX) recently closed the acquisition of Russia-based Natur Produkt ...
